Eloxx Pharmaceuticals (OTCMKTS:ELOX) – SunTrust Banks boosted their Q2 2019 earnings per share estimates for shares of Eloxx Pharmaceuticals in a note issued to investors on Monday, May 13th. SunTrust Banks analyst E. Nash now anticipates that the company will post earnings of ($0.40) per share for the quarter, up from their prior estimate of ($0.48). SunTrust Banks also issued estimates for Eloxx Pharmaceuticals’ Q3 2019 earnings at ($0.43) EPS, Q4 2019 earnings at ($0.46) EPS, FY2019 earnings at ($1.64) EPS, FY2020 earnings at ($1.41) EPS, FY2021 earnings at ($1.45) EPS, FY2022 earnings at ($1.32) EPS and FY2023 earnings at ($0.92) EPS.
ELOX has been the topic of a number of other research reports. Zacks Investment Research downgraded Eloxx Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, March 13th. Canaccord Genuity restated a “buy” rating and issued a $17.00 target price (down previously from $20.00) on shares of Eloxx Pharmaceuticals in a research note on Wednesday. They noted that the move was a valuation call. One research analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Eloxx Pharmaceuticals currently has a consensus rating of “Buy” and an average price target of $19.40.
Shares of ELOX opened at $10.66 on Thursday. Eloxx Pharmaceuticals has a 52 week low of $9.12 and a 52 week high of $24.60.
Eloxx Pharmaceuticals (OTCMKTS:ELOX) last issued its earnings results on Thursday, May 9th. The company reported ($0.33) EPS for the quarter, topping analysts’ consensus estimates of ($0.41) by $0.08.
Several institutional investors and hedge funds have recently modified their holdings of ELOX. BlackRock Inc. boosted its position in Eloxx Pharmaceuticals by 36.9% during the fourth quarter. BlackRock Inc. now owns 1,493,471 shares of the company’s stock worth $17,938,000 after purchasing an additional 402,501 shares in the last quarter. Vanguard Group Inc boosted its position in Eloxx Pharmaceuticals by 60.0% during the third quarter. Vanguard Group Inc now owns 857,202 shares of the company’s stock worth $14,606,000 after purchasing an additional 321,328 shares in the last quarter. Vanguard Group Inc. boosted its position in Eloxx Pharmaceuticals by 60.0% during the third quarter. Vanguard Group Inc. now owns 857,202 shares of the company’s stock worth $14,606,000 after purchasing an additional 321,328 shares in the last quarter. MetLife Investment Advisors LLC purchased a new position in Eloxx Pharmaceuticals during the third quarter worth approximately $381,000. Finally, Geode Capital Management LLC boosted its position in Eloxx Pharmaceuticals by 10.0% during the fourth quarter. Geode Capital Management LLC now owns 237,986 shares of the company’s stock worth $2,858,000 after purchasing an additional 21,634 shares in the last quarter.
Eloxx Pharmaceuticals Company Profile
Eloxx Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics for the treatment of rare and ultra-rare premature stop codon diseases. Its lead program is ELX-02, which is in Phase I clinical trial, which focuses on the treatment of cystic fibrosis and cystinosis patients with diagnosed nonsense mutations.
Receive News & Ratings for Eloxx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eloxx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.